ProMIS Neurosciences (TSX:PMN) has appointed Johanne Kaplan to the post of chief development officer to focus on supporting the design and execution of the company’s development programs and partnering efforts.
Dr. Kaplan joins ProMIS following 24 years at Genzyme, where she held positions of increasing responsibility, culminating in her decade-long tenure as VP of Research, most recently directing the multiple sclerosis and neuroimmunology research effort.
In addition, her experience as a senior executive in pharmaceutical industry in-licensing and product acquisition will be integral as the company pursues partnering opportunities, he added.
ProMIS is developing precision medicine treatments for neurodegenerative diseases, particularly Alzheimer’s disease and ALS.
